We describe and discuss microscopic findings in the brown adipose tissue (BAT) blood vessels of Han Wistar rats treated with GI262570X, a peroxisome proliferator-activated receptor-γ agonist (PPAR-γ agonist) by oral gavage for 28 days, 13 weeks, 27 weeks, and 2 years. Review of these studies revealed a consistent vascular change, consisting of multifocal fatty infiltration in the BAT of treated rats. A similar vascular change was not seen in other vessels or organs. Microscopically, fatty infiltration was characterized primarily by round, clear vacuoles within the tunica media and/or tunica adventitia of small and medium-sized arteries and arterioles. Occasionally, these vacuoles had peripherally located nuclei and morphologically resembled adipocytes, suggesting a well-characterized PPAR effect (ie, differentiation of stem cells or preadipocytes into mature adipocytes). However, administration of GI262570X up to 2 years failed to induce more severe or progressive lesions in the blood vessels of rat BAT and, in particular, did not result in induction of any atherosclerotic-like lesions or foam cell infiltration. At the longer exposure, there was an apparent reduction of severity and/or incidence, indicating a possible adaptive response. These results suggest that the possibility of generating atherosclerotic-like lesions through prolonged treatment of GI262570X (PPAR-γ agonist) is highly unlikely in rats.
INTRODUCTION Peroxisome
proliferator-activated receptor-gamma (PPAR-γ ) is a member of the nuclear receptor subfamily of genes that encode receptors for steroid and thyroid hormones, vitamin D, and retinoic acid. PPAR-γ plays a critical role in adipocyte differentiation and fat deposition, and is predominantly expressed in brown and white adipose tissues and, to lesser extent, in the large intestine, the retina, and some parts of the immune system (4, 27) . Activation of PPAR-γ by agonists like the thiazolidinedione (TZD) class of compounds triggers terminal differentiation of preadipocytes into mature adipocytes and promotes lipid storage (11, 27) . The PPAR-γ agonists rosiglitazone, pioglitazone, and troglitazone are TZDs that have been used as insulin sensitizers for the treatment of Type II diabetes. These drugs produce their antihyperglycemic effect by selectively enhancing or partially mimicking certain actions of insulin and thereby increasing insulin-dependent glucose disposal and reducing hepatic glucose output (23) .
Recently, PPARs have emerged in the area of vascular biology and atherosclerosis with results of the most comprehensive study confirming the existence of PPAR-γ in the vascular wall of humans and rats (22) . Experimental studies indicate that PPAR-γ may have a preventive role in the pathogenesis of atherosclerosis by regulating cytokine production, adhesion molecule expression on endothelial cells, fibrinolysis, modulation of monocyte-derived macrophages, and regulation of vascular smooth muscle cell proliferation (22, 23) . In patients with type II diabetes, troglitazone, or pioglitazone has been shown to decrease the carotid arterial wall thickness (measured by B-mode ultrasound), a marker of early stages of atherosclerosis (20, 28) . On the other hand, in vitro data from Tontonoz et al (37) and Nagy et al (31) suggest that PPAR-γ is upregulated in activated macrophages and might increase foam cell differentiation and activity to internalize oxidized low density lipoprotein (LDL), an undesirable cardiovascular effect. Certainly, addressing both protective and undesirable vascular effects requires a better understanding of PPAR-γ agonist and its long-term vascular effects. 420 0192-6233/02$3.00+$0.00
Brown adipose tissue (BAT), sometimes referred to as the "hibernating gland" is distributed throughout the ventral, lateral, and dorsal aspects of the neck and is a major component found in the rodent interscapular region. BAT is also located around large vessels and plays a critical role in postnatal thermogenesis in rodents (5, 38) . Microscopically, BAT is made up of lobules containing adipocytes with small lipid droplets giving it a multilocular appearance, and high-density mitochondria. A network of collagen fibers that contain numerous blood vessels surrounds brown adipocytes. It is estimated in rats that vascularity in BAT is 4 to 6 times greater than that of the white adipose tissue (1) .
GI262570X is a new L-tyrosine-based, non-TZD PPAR-γ agonist, developed by GlaxoSmithKline Inc for the treatment of human Type II diabetes. Several preclinical studies have been conducted in various laboratory species, including rats. This report reviews the effects of GI262570X on the blood vessels of rat brown adipose tissue and evaluates the vascular effects after various treatment durations to better understand potential long-term consequences following GI262570X administration, especially whether the PPAR-γ -induced vascular lesion is likely to progress to a more serious condition, eg, atherosclerosis.
MATERIALS AND METHODS
This report includes review of 4 toxicity studies in rats: 1-month, 13-week, 27-week, and 2-year (lifetime). Han Wistar rats (Taconic Farms, Germantown, NY, USA), 7-9 weeks old, weighing approximately 159.1-295.8 g and 129.0-200.7 g for males and females, respectively were used in oral toxicity studies. For the 2-year study, animals were 4 weeks old, weighing approximately 102.8-183.3 g for males and 96.9-146.5 g for females. Animals were allowed ad libitum access to water and Purina rodent chow (PMI Feeds, St Louis, MO, USA), and were dosed daily by oral gavage with vehicle (0.5% hydroxypropylmethylcellulose and 0.1% Tween 80) or test compound (GI262570X) at specified mg of compound per kg animal weight (0.5-100 mg/kg/day) for 28 days (1-month study), 13 weeks (13-week study), 27 weeks (27-week study), and 2 years (2-year lifetime study). At the study termination, animals were euthanized and received a complete gross evaluation at necropsy. A standard set of protocol tissues, including interscapular BAT depot were fixed in 10% neutral buffered formalin, processed, sectioned, and stained with hematoxylin and eosin (H&E). The H&E stained tissue sections from each study were examined by a study pathologist with subsequent peer-review by another pathologist. Both study and peer-review pathologists were different for each of the studies. Lesions were described and subjectively scored, as needed, using 4 grades: (1) minimal lesion, (2) mild lesion, (3) moderate lesion, and (4) severe lesion. Severity scores for the BAT vessels were based on the number and size of changes within the vascular wall.
Because of a vascular change, noted only in the BAT of treated rats in all studies, BAT sections were obtained from the archives and reviewed by the senior author and Thomas Brodie (2-year study only) for consistent grading and recording of vascular findings. The data from each study (only animals that survived to the end of study) were tabulated and analyzed.
Statistics. Results from 13-week, 27-week, and 2-year studies were analyzed by Fisher's Exact test and p values of less than 0.05 were considered statistically significant.
RESULTS
Minimal to mild, multifocal vascular fatty infiltration, characterized by an increase in the size and number of lipid droplets within the wall of arteries and arterioles of brown adipose tissue, was noted in rats treated with GI262570X. In H&E stained sections, these lipid droplets were seen as round, clear vacuoles, mostly within the tunica media and/or adventitia of primarily small and medium-sized arteries and arterioles (Figures 1-4) . Occasionally, these vacuoles had small, thin, peripherally located basophilic nuclei. Morphologically they resembled adipocytes. A similar vascular change was not seen in other vessels or organs, suggesting the vasculature of BAT is a unique target tissue. In all studies, males exhibited relatively higher severity grades as compared to females (Table 1) . Most importantly, atherosclerotic-like lesions, such as foam cell and/or inflammatory cell infiltration, smooth muscle cell proliferation, fibrous cap, and a central lipid core with typical cholesterol clefts were not detected in any of the BAT vessels in any study. The vascular change was noted at 100-(1-month study), 50-(13-week and 27-week studies), 20-(2-year study), 10-(2-year study), and 5 mg/kg/day (13-week and 27-week studies) dose groups. The lower dose groups in 1-month (0.5-and 10 mg/kg/day), 13-week (0.5 mg/kg/day), 27-week (0.5 mg/kg/day) and 2-year (0.5 mg/kg/day) studies were not affected. Therefore, the dose groups included in this review were 100-(1-month), 50-(13-week and 27-week), 20-(2-year), 10-(2-year), and 5 mg/kg/day (13-week and 27-week). Prior to these toxicity studies, exploratory (mechanistic) rat studies were performed to further identify the nature of vacuoles within the affected vascular wall using special lipid stains and transmission electron microscopy (TEM). Oil red O and osmium stains of the affected vessels revealed a positive reaction for lipid droplets. The ultrastructural features were also consistent with differentiated adipocytes. However, results of exploratory studies were not included in this review.
There was no increase in either sex, in the severity or incidence of vascular fatty infiltration in the 27-week study at 5-and 50 mg/kg/day dose groups when compared to that of the 13-week toxicity study (Table 2) . On the contrary, a statistically significant decrease in the severity of vascular fatty infiltration was observed in the 27-week compared to the 13-week study. In both males and females, the severity of vascular fatty infiltration was decreased ( p < 0.05 or p < 0.01) in the 50 mg/kg/day dose group at the 27-week study as compared to the severity at the same dose at 13-week. A similar decrease ( p < 0.01) in severity and incidence was noted in the 5 mg/kg/day dose group females, but not in the 5 mg/kg/day dose group males. A 2-year lifetime study demonstrated that GI262570X produced a significant reduction in the incidence of vascular fatty infiltration even at higher doses (10-and 20 mg/kg/day) and longer exposure than that of 13-week or 27-week studies at the 5 mg/kg/day (Table 3) . and arterioles of rat brown adipose tissue, was noted in rats treated with GI262570X. Exploratory studies using special lipid stains (Oil red O and osmium) and TEM revealed differentiated adipocytes and not foam cells or macrophages, suggesting a well-characterized PPAR effect, ie, differentiation of preadipocytes or stem cells into mature adipocytes (27) . The site-specific occurrence of this lesion might be related to high-level expression of PPAR-γ in the rat brown adipose tissue (4) .
Prolonged administration of GI262570X (PPAR-γ agonist) did not induce atherosclerotic-like lesions or foam cell (macrophage) infiltration in the blood vessels of rat BAT nor result in progression of the vascular fatty infiltration or adipocyte differentiation seen after 1 month of dosing. Instead, there was an apparent reduction in the severity or incidence of vascular fatty infiltration or adipocyte differentiation in the BAT at the longer-exposure time points, indicating an adaptive response or reversibility. In vitro studies indicate that PPAR-γ can induce monocyte differentiation and expression of the scavenger receptor CD36, which in turn facilitates in- Significance of difference in a pair-wise (Fisher's) test between 13-week (or 27-week) and 2-year studies for 5-, 10-, and 20 mg/kg/day dose groups: * * p < 0.01.
creased uptake of oxLDL and foam cell formation (31, 37) . However, there is recent evidence to show that treatment with TZDs divergently regulated CD36 and class-A macrophage scavenger receptor expression and failed to induce significant cellular cholesterol accumulation, suggesting that TZDs may not exacerbate macrophage foam-cell formation (29) . Furthermore, PPAR-γ has been shown to promote cholesterol efflux from the macrophage foam cell, a potential explanation for the observation that TZDs actually improve atherosclerosis in vivo despite their activity to induce CD36 expression in macrophages (6) . Similarly, troglitazone has been shown to inhibit fatty streak lesion formation in apolipoprotein E-knockout and low-density lipoprotein receptor-deficient mice fed with a high-fat diet and/or a high fructose diet (7, 8) .
The PPARs (PPAR-α and PPAR-γ ) exert their beneficial effects through regulation of chemokines, cytokine production, adhesion molecule expression on the endothelial cells, fibrinolysis, VSMC proliferation and modulation of monocyte-derived macrophages (17, 23, 24, 30) . Chemotactic attraction of inflammatory cells by various chemokines is one of the first steps in atherosclerosis. PPAR agonists have been shown to inhibit expression of CXC-chemokines, such as gamma interferon (IFN-gamma)-inducible protein 10 (IP-10), monokine induced by IFN-gamma (Mig), and inducible T-cell alpha-chemoattractant (I-TAC) (24) , and a CCchemokine, monocyte chemoattractant protein-1 (MCP-1) (30). MCP-1, produced by vascular endothelial cells, is known to play an important role in the pathogenesis of atherosclerosis through the induction of monocyte migration (32) . The PPAR agonist inhibits production of MCP-1 in cytokine (interleukin-1β or tumor necrosis factor-α) treated human vascular endothelial cells (32) . The importance of MCP-1 in atherosclerosis has been recently recognized by using apo E knockout and LDL-R knockout mouse models. In these animal models, atherosclerotic lesions were markedly reduced when MCP-1 was also knocked out (3, 15, 35) .
Macrophages play a critical role in atherosclerosis by secreting substances that contribute to atherosclerotic plaque formation. It has been shown that PPAR-γ agonists inhibit activation of macrophages (36) and decrease production of inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1beta (IL-1β), interleukin-6 and inducible gelatinase B, matrix metalloproteinase-9 (MMP-9), or scavenger receptor A (18, 26) . Plutzky (34) reported that the expression of PPAR-γ in monocytes/macrophages in human atheroma, with activation of PPAR-γ in human monocyte-derived macrophages by PPAR-γ agonists inhibited MMP-9 expression and functional gelatinolytic activity in a dose-dependent manner. Because MMP-9 is responsible for degradation of collagen and other matrix components of vessel walls such as elastin, its inhibition would be expected to be protective.
Expression of adhesion molecules on the endothelial cell surface is also critical for recruitment of leukocytes to the atherosclerotic site. More recently, PPAR-γ activators have been found to inhibit the expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) in activated human endothelial cells (33) . In human umbilical vein endothelial cells, troglitazone has been shown to reduce the expression of VCAM-1, ICAM-1, and E-selectin induced by tumor necrosis factor-α alone or in combination with different amounts of oxidized LDL; this reduction was paralleled by a significant fall in nuclear factor-κB (NF-κB) translocation, suggesting that troglitazone may have prevented NF-κB-mediated adhesion molecule expression by exerting its antioxidant effect on oxygen-derived free radicals (9) . In addition, PPAR-γ agonists may have a therapeutic potential for improving endothelial dysfunction by down-regulating the gene expression of plasminogen activator type-1, a major physiologic inhibitor of fibrinolysis (19) .
Proliferation and migration of VSMC are critical events in the progression of atherosclerosis. PPAR-γ is expressed in both human VSMC and endothelial cells, and troglitazone, pioglitazone or rosiglitazone have been shown to inhibit the proliferation and migration of VSMC stimulated by growth factors such as insulin, epidermal growth factor, plateletderived growth factor and basic fibroblast growth factor (12, 14, 21) . In atherosclerosis, VSMCs migrate into and within intima through the activation of MMP-9. Recently, PPAR-γ agonist has been shown to inhibit expression and functional activity of MMP-9 in VSMCs (21, 25) . Endothelin-1 (ET-1), another vasoactive peptide, mainly produced by vascular endothelial cells, is involved in regulation of vascular tone and VSMC proliferation. PPAR-γ agonist inhibits thrombininduced ET-1 biosynthesis, indicating a novel role in vascular endothelial function (10) . In human aorta and coronary artery myocytes in vitro, PPAR agonist attenuates mitogen-induced DNA synthesis, inhibits cell migration, prevents c-fos expression, and also inhibits intimal hyperplasia in normal and insulin-resistant rats in vivo (2) . More recently, troglitazone has been found to up-regulate cytokine-stimulated nitric oxide (NO) synthesis in the VSMC which may have important implications for inhibition of atherosclerosis, because NO plays a preventive role (16) . In addition, troglitazone inhibits both angiotensin II-induced nuclear translocation of extracellular signal-regulated kinase 1/2 and the nuclear activity of its upstream signaling kinase, protein kinase Cζ in rat aortic smooth muscle cells (13) . Because extracellular signal-regulated kinase 1/2 nuclear translocation may be a critical signaling step for multiple growth factors that stimulate VSMC proliferation and migration, troglitazone may provide a new therapeutic for the prevention and treatment of atherosclerosis (13) .
Taken together, published scientific reports strongly support an inhibitory role of PPAR-γ in the development of atherosclerosis. Therefore, the possibility of generating atherosclerotic-like lesions through a prolonged treatment of PPAR-γ agonist is highly unlikely, and was supported by GI262570X studies in rats.
CONCLUSIONS
Results from the 1-month, 13-week, 27-week, and 2-year (lifetime) oral toxicity studies demonstrate that prolonged administration of a PPAR-γ agonist (GI262570X) does not induce more severe or progressive lesions in the blood vessel of rat BAT and, in particular, did not result in induction of any atherosclerotic-like lesions or foam cell infiltration. Furthermore, at the longer exposure, there was an apparent reduction of severity and incidence of vascular fatty infiltration or adipocyte differentiation in the BAT, indicating a possible adaptive response. These results suggest that generation of atherosclerotic-like lesions by prolonged treatment with PPAR-γ agonist (GI262570X) is highly unlikely in Han Wistar rats.
